cyc 202 has been researched along with bs 194 in 3 studies
Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (bs 194) | Trials (bs 194) | Recent Studies (post-2010) (bs 194) |
---|---|---|---|---|---|
979 | 7 | 393 | 11 | 0 | 9 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Aboagye, EO; Ali, S; Alikian, M; Barbazanges, M; Barrett, AG; Blum, A; Brackow, J; Coombes, RC; Freemont, PS; Fuchter, MJ; Hazel, P; Heathcote, DA; Jogalekar, AS; Kanneganti, SK; Kroll, SH; Liotta, DC; Pace, RD; Patel, H; Periyasamy, M; Scheiper, B; Siwicka, A; Snyder, JP | 1 |
de Dios, A; Lallena, MJ; Sánchez-Martínez, C; Sanfeliciano, SG | 1 |
George, RF; Georgey, HH; Hassan, GS; Mahmoud, WR; Mohammed, EZ; Omar, FA | 1 |
1 review(s) available for cyc 202 and bs 194
Article | Year |
---|---|
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinases; Drug Discovery; Humans; Indoles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Transcription Factors | 2019 |
2 other study(ies) available for cyc 202 and bs 194
Article | Year |
---|---|
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Female; Humans; In Vitro Techniques; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Phosphorylation; Protein Binding; Pyrazoles; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quantitative Structure-Activity Relationship | 2021 |